| Abbreviation | Explanation |
| IL-1β | Interleukin-1 beta |
| IL-6 | Interleukin-6 |
| IL-8 | Interleukin-8 (also known as CXCL8) |
| IL-10 | Interleukin-10 |
| IL-12 | Interleukin-12 |
| IL-17 | Interleukin-17 |
| IFN-γ | Interferon-gamma |
| TNF-α | Tumor Necrosis Factor-alpha |
| TGF-β | Transforming Growth Factor-beta |
| CXCL8 | C-X-C motif chemokine ligand 8 (synonymous with IL-8) |
| CXCR1/2 | C-X-C motif chemokine receptor 1 and 2 |
| CCL2 | C-C motif chemokine ligand 2 |
| CCL5 | C-C motif chemokine ligand 5 |
| CXCL12 | C-X-C motif chemokine ligand 12 |
| CXCR4 | C-X-C motif chemokine receptor 4 |
| EMT | Epithelial–Mesenchymal Transition |
| TAM | Tumor-Associated Macrophage |
| MDSC | Myeloid-Derived Suppressor Cell |
| NK cell | Natural Killer cell |
| Treg | Regulatory T cell |
| Th1 | T helper 1 (pro-inflammatory, cell-mediated immunity) |
| Th2 | T helper 2 (anti-inflammatory, humoral immunity) |
| Th17 | T helper 17 (subset producing IL-17) |
| STAT3 | Signal Transducer and Activator of Transcription 3 |
| NF-κB | Nuclear Factor kappa-light-chain-enhancer of activated B cells |
| MAPK | Mitogen-Activated Protein Kinase |
| JAK | Janus Kinase |
| HR | Hazard Ratio |
| OR | Odds Ratio |
| CI | Confidence Interval |
| OS | Overall Survival |
| DFS | Disease-Free Survival |
| ELISA | Enzyme-Linked Immunosorbent Assay |
| IHC | Immunohistochemistry |
| TCGA | The Cancer Genome Atlas |
| TNBC | Triple-Negative Breast Cancer |
| PD-L1 | Programmed Death-Ligand 1 |
| PD-1 | Programmed Death-1 (immune checkpoint receptor) |
| TAZ | Transcriptional co-activator with PDZ-binding motif (in Hippo signaling pathway) |
| mRNA | Messenger Ribonucleic Acid |